Xiongwei Shi

Title: Innovations by Xiongwei Shi

Introduction

Xiongwei Shi is a notable inventor based in Edison, NJ (US). He has made significant contributions to the field of chemistry, particularly in the development of compounds that act as CCR5 receptor antagonists. With a total of 3 patents to his name, his work has implications for various therapeutic applications.

Latest Patents

Xiongwei Shi's latest patents include the synthesis of CCR5 receptor antagonists. This invention focuses on the synthesis of a specific compound, 4-[4-[(R)-[1-[cyclopropylsulfonyl)-4-piperidinyl](3-fluorophenyl)methyl]-3(S)-methyl-1-piperazinyl]-1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-methylpiperidine], along with its intermediates from readily available starting materials through a novel route. Another significant patent involves the synthesis of piperidine and piperazine compounds as CCR5 antagonists, which discloses novel processes to prepare specific compounds.

Career Highlights

Xiongwei Shi is currently associated with Schering Corporation, where he continues to innovate and contribute to the field of pharmaceutical chemistry. His work has been instrumental in advancing the understanding and development of therapeutic agents.

Collaborations

Xiongwei has collaborated with notable colleagues, including William W Leong and Man Zhu, enhancing the research and development efforts within his field.

Conclusion

Xiongwei Shi's contributions to the field of chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in therapeutic applications.